Indivior Pharmaceuticals (INDV) Stock Could Be 23% Undervalued As Cost Cut Narrative Builds

Indivior Pharmaceuticals (INDV) is back in focus after fresh attention on its role in treating opioid dependence, prompting investors to reassess the stock’s recent performance and current valuation based on publicly available financial metrics.

See our latest analysis for Indivior Pharmaceuticals.

The recent focus on Indivior Pharmaceuticals comes against a backdrop of steady gains, with a 30.72% 90 day share price return and a very strong 1 year total shareholder return of 175.54%, suggesting momentum has been building rather than fading.

If renewed interest in opioid treatment has you rethinking your portfolio, it could be a good moment to widen your research and check out 41 healthcare AI stocks

With Indivior Pharmaceuticals posting a 30.72% 90 day share price return and trading at a reported 69.88% intrinsic discount, the key question is whether the stock is still undervalued or if markets are already pricing in future growth.

Most Popular Narrative: 23.4% Undervalued

Compared with Indivior Pharmaceuticals' last close at $38.30, the most followed narrative points to a fair value of about $50.00 using a detailed cash flow approach.

The Indivior Action Agenda includes Phase 1, which is focused on simplifying the business, and Phase II, Accelerate, which is set to start in 2026. This plan is expected to reduce nonessential spend by at least US$150 million a year and cap 2026 operating expenses at US$450 million, which directly supports adjusted EBITDA growth and free cash flow.

Read the complete narrative.

Want to understand why this OUD focused business is being valued above today’s price? The narrative leans heavily on steadier revenues, wider margins and a very different earnings profile a few years out. Curious which combination of growth, profitability and discounting assumptions gets to that $50 handle?

Result: Fair Value of $50.00 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this Indivior Pharmaceuticals narrative depends heavily on SUBLOCADE adoption in a still nascent long acting injectable market, as well as sustained cost cuts that might eventually constrain growth.

Find out about the key risks to this Indivior Pharmaceuticals narrative.

Next Steps

With sentiment split between those focused on opportunities and those focused on risks, it makes sense to move quickly and test the numbers yourself. A good place to start is with a close look at the 4 key rewards and 3 important warning signs

Looking for more investment ideas beyond Indivior Pharmaceuticals?

If you are serious about putting the Indivior Pharmaceuticals story in context, do not stop here, use data driven stock lists to spot what others might miss.

• Pinpoint potential bargains early by scanning companies that combine quality fundamentals with attractive pricing through the screener containing 20 high quality undiscovered gems.
• Strengthen the core of your portfolio by reviewing businesses with robust finances using the solid balance sheet and fundamentals stocks screener (48 results).
• Reduce portfolio stress by focusing on steadier candidates highlighted in the 65 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com